Teva Faces EU Antitrust Probe Over MS Drug Patent Strategy

Law360 (March 4, 2021, 7:17 PM EST) -- European enforcers are investigating Teva over concerns the pharmaceutical company delayed the emergence of generic competitors to its blockbuster multiple sclerosis drug Copaxone by misusing patent procedures and disparaging rivals.

The European Commission said Thursday it has opened a formal probe to assess whether Teva has abused the dominant market position of its branded version of glatiramer acetate in violation of the bloc's competition laws. The commission said in a statement that enforcers will focus on allegations that Teva abused the patent process and used a communications campaign to hinder its rivals, the agency's first look at such conduct in the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!